Brief: Pharvaris NV - Expects Rapide-3 Data Announcement In Q4 2025
Brief: Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update
Pharvaris NV expected to post a loss of 76 cents a share - Earnings Preview
Pharvaris NV reports results for the quarter ended December 31 - Earnings Summary
Pharvaris NV expected to post a loss of 72 cents a share - Earnings Preview
Brief: Pharvaris Announces Data Highlighting Deucrictibant For The Treatment Of HAE To Be Presented At Upcoming Scientific Meetings
Pharvaris NV reports results for the quarter ended in June - Earnings Summary
Pharvaris NV expected to post a loss of 55 cents a share - Earnings Preview
Pharvaris NV expected to post a loss of 56 cents a share - Earnings Preview
Brief: Pharvaris NV Files For Mixed Shelf Offering Size Not Disclosed
Brief: Pharvaris Appoints David Nassif, J.D., As CFO
Pharvaris NV expected to post a loss of 53 cents a share - Earnings Preview
Pharvaris rises as FDA lifts clinical hold of hereditary disease drug
Brief: Pharvaris NV Announces FDA Lifting Of Clinical Hold Of Deucrictibant For The Prophylactic Treatment Of Hae Attacks
Founder Jochen Knolle To Transition As Strategic Advisor To CEO
U.S. STOCKS ON THE MOVE-Vera Bradley, Shake Shack, 2seventy Bio
U.S. STOCKS ON THE MOVE-Citigroup, Regeneron, Ormat
U.S. STOCKS ON THE MOVE-Coya, AeroVironment, Cleveland-Cliffs
Brief: Pharvaris NV Pricing Of Underwritten Offering Of 11.1 Million Ordinary Shares At $24.00 Per Share